Cytovance Biologics Inc. Names Martin LeBlanc to Board of Directors

Published: May 09, 2012

OKLAHOMA CITY, OK--(Marketwire - May 08, 2012) - Cytovance® Biologics, a leading full-service contract manufacturer ("CMO") of mammalian and microbial biologics, announces the appointment of Martin LeBlanc to the company's Board of Directors. Mr. LeBlanc is the President and Chief Executive Officer of Caprion Proteomics, Inc. of Montreal, QC, Canada.

"We welcome Martin as our newest board member and look forward to his contributions as an experienced corporate growth leader," said Darren Head, President and Chief Executive Officer of Cytovance Biologics. "Martin's more than 20 years of leadership experience and insight in life sciences complements the Cytovance mission of providing integral pathways of converting today's novel protein discoveries into future life saving therapies."

As co-founder of Caprion, Mr. LeBlanc led the development of Caprion's leading proteomics technology and of its profitable and rapidly growing service business in the field of drug discovery and personalized medicine, by building successful customer relationships and strategic alliances with over 30 major pharmaceutical and biotechnology companies as well as with leading government agencies and academic institutions. Prior to Caprion, he began his professional career as a management consultant with McKinsey & Company. He then initiated his career as a biotech entrepreneur at Advanced Bioconcept, initially as Vice-President of Sales & Marketing and then as General Manager following the company's acquisition by NEN Life Sciences (now part of Perkin-Elmer).

Mr. LeBlanc is currently a member of the Governing Council of the Canadian Institutes of Health Research (CIHR), and of the Board of Directors of Victhom Human Bionics, Soricimed BioPharma, Montreal In-Vivo and the Atlantic Cancer Research Institute. He earned his bachelor's degree in Economics from the University of Moncton prior to completing an M.A. in Economics and Politics at Oxford University as a Rhodes Scholar.

About Cytovance® Biologics

Cytovance® Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities.

Learn more about Cytovance Biologics at www.cytovance.com.